BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has scheduled the release of its 2024 financial results for Thursday, March 27, 2025, after market close. The company's management team will conduct a conference call following the announcement to discuss the financial performance and provide updates on business operations.
Investors and interested parties can access the live broadcast and archived recording of the conference call through the company's website at biorestorative.com/investor-relations under the Events section.
BioRestorative Therapies (NASDAQ:BRTX), un'azienda di medicina rigenerativa in fase clinica specializzata in terapie basate su cellule staminali, ha programmato il rilascio dei suoi risultati finanziari 2024 per giovedì 27 marzo 2025, dopo la chiusura del mercato. Il team di gestione dell'azienda condurrà una conferenza telefonica dopo l'annuncio per discutere le performance finanziarie e fornire aggiornamenti sulle operazioni aziendali.
Gli investitori e le parti interessate possono accedere alla trasmissione in diretta e alla registrazione archiviata della conferenza telefonica attraverso il sito web dell'azienda all'indirizzo biorestorative.com/investor-relations nella sezione Eventi.
BioRestorative Therapies (NASDAQ:BRTX), una empresa de medicina regenerativa en etapa clínica especializada en terapias basadas en células madre, ha programado la publicación de sus resultados financieros de 2024 para el jueves 27 de marzo de 2025, después del cierre del mercado. El equipo de gestión de la empresa llevará a cabo una llamada de conferencia tras el anuncio para discutir el rendimiento financiero y proporcionar actualizaciones sobre las operaciones comerciales.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo y a la grabación archivada de la llamada de conferencia a través del sitio web de la empresa en biorestorative.com/investor-relations en la sección de Eventos.
BioRestorative Therapies (NASDAQ:BRTX), 줄기세포 기반 치료를 전문으로 하는 임상 단계 재생 의학 회사는 2024년 재무 결과를 2025년 3월 27일 목요일, 시장 종료 후 발표할 예정입니다. 회사의 경영진은 발표 후 재무 성과를 논의하고 사업 운영에 대한 업데이트를 제공하기 위해 컨퍼런스 콜을 진행할 것입니다.
투자자 및 관심 있는 분들은 biorestorative.com/investor-relations의 이벤트 섹션을 통해 회사 웹사이트에서 컨퍼런스 콜의 생중계 및 아카이브된 녹음에 접근할 수 있습니다.
BioRestorative Therapies (NASDAQ:BRTX), une entreprise de médecine régénérative en phase clinique spécialisée dans les thérapies à base de cellules souches, a prévu la publication de ses résultats financiers 2024 pour le jeudi 27 mars 2025, après la fermeture du marché. L'équipe de direction de l'entreprise animera une conférence téléphonique après l'annonce pour discuter des performances financières et fournir des mises à jour sur les opérations commerciales.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à l'enregistrement archivé de la conférence téléphonique via le site Web de l'entreprise à l'adresse biorestorative.com/investor-relations dans la section Événements.
BioRestorative Therapies (NASDAQ:BRTX), ein Unternehmen für regenerative Medizin in der klinischen Phase, das auf stamzellenbasierte Therapien spezialisiert ist, hat die Veröffentlichung seiner finanziellen Ergebnisse für 2024 für Donnerstag, den 27. März 2025, nach Börsenschluss angesetzt. Das Management-Team des Unternehmens wird nach der Bekanntgabe eine Telefonkonferenz abhalten, um die finanzielle Leistung zu besprechen und Updates zu den Geschäftstätigkeiten bereitzustellen.
Investoren und interessierte Parteien können die Live-Übertragung und die archivierte Aufnahme der Telefonkonferenz über die Unternehmenswebsite unter biorestorative.com/investor-relations im Bereich Veranstaltungen abrufen.
- None.
- None.
MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its 2024 financial results after market close on Thursday, March 27, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.
2024 Results Conference Call Details:
| Date: | Thursday, March 27, 2025 |
| Time: | 4:30 p.m. ET |
| Domestic: | 1-888-506-0062 |
| International: | 1-973-528-0011 |
| Access Code: | 726526 |
The call will also be broadcast live and archived on the Company's website at https://www.biorestorative.com/investor-relations/ under “Events.”
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained FDA IND clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ
When will BioRestorative Therapies (BRTX) release its 2024 financial results?
How can investors access BRTX's 2024 financial results conference call?
What is BioRestorative Therapies' (BRTX) main business focus?
What will be discussed in BRTX's March 27, 2025 conference call?
